A 42-year-old woman with a history of atrial fibrillation presents to the outpatient clinic with a 5-day history of productive cough and fever. She is currently on digoxin 0.25 mg daily for rate control. Clinical examination reveals left lower lobe consolidation. Chest X-ray confirms community-acquired pneumonia. Blood cultures are pending. She has no penicillin allergy. Which of the following macrolides would be the LEAST appropriate choice for this patient and why?

Question

Accepted Answer

C. Erythromycin, because it is a potent CYP3A4 inhibitor and significantly increases digoxin levels. ## Clinical Context
This patient requires antibiotic therapy for community-acquired pneumonia but is at high risk for drug interactions due to concurrent digoxin therapy for atrial fibrillation.

## Macrolide Metabolism and CYP3A4 Inhibition

| Macrolide | CYP3A4 Inhibition | Digoxin Interaction | Clinical Significance |
|-----------|-------------------|--------------------|-----------------------|
| Erythromycin | **Potent** | **Marked increase** | Digoxin toxicity risk |
| Clarithromycin | Moderate | Moderate increase | Caution required |
| Azithromycin | Minimal | Minimal | Safe choice |
| Roxithromycin | Mild | Mild | Generally safe |

**Key Point:** Erythromycin is a potent inhibitor of CYP3A4, the enzyme responsible for digoxin metabolism. This leads to increased serum digoxin levels and risk of toxicity (arrhythmias, nausea, visual disturbances).

**High-Yield:** Among macrolides, azithromycin has the **lowest potential for drug interactions** and is the preferred choice in patients on digoxin or other CYP3A4-metabolized drugs.

**Clinical Pearl:** Digoxin has a narrow therapeutic window (0.5–2 ng/mL). Even modest increases in serum levels can precipitate toxicity, especially in elderly patients or those with renal impairment.

**Warning:** Erythromycin should be avoided in patients on digoxin unless serum digoxin levels are monitored closely and the dose is reduced.

## Why Azithromycin Is Preferred
- Minimal CYP3A4 inhibition
- No clinically significant interaction with digoxin
- Excellent lung penetration
- Suitable for both inpatient and outpatient therapy
- Macrolide of choice in polypharmacy scenarios

[cite:KD Tripathi 8e Ch 48]

Answer

A. Clarithromycin, because it is a moderate CYP3A4 inhibitor with potential for digoxin toxicity

Answer

B. Azithromycin, because it has minimal interaction with digoxin and is suitable for outpatient therapy

Answer

D. Roxithromycin, because it has lower CYP3A4 inhibition compared to erythromycin

Explanation

Practice similar questions